Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.

Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of others, such as bowel and breast cancers. But it has been unclear to what extent tumour necrosis factor (TNF) inhibitors - drugs which act on the immune system - might affect risk.

TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept.

The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. In all, this provided information on more than 40,000 patients and almost 150,000 cumulative years of exposure to these drugs.

The studies were drawn from an extensive trawl of clinical research databases, and findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The pooled risk from seven studies for the development of any cancer showed that there was negligible or no increased risk, overall.

Two studies indicated that there was no evidence that patients taking TNF inhibitors over the long term were at increased risk of cancer either. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors.

But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors were 79% more likely to develop a melanoma than patients not taking these drugs.

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add.

Provided by British Medical Journal (news : web)

Public release date: 7-Sep-2011
[ | E-mail | Share ]

Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University

New 'bouncer' molecule halts rheumatoid arthritis

Protective protein prevents immune system from ravaging joints and bones

CHICAGO -- Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons.

The Feinberg School team has identified this bouncer, a protein called P21, which prevents immune cells from launching into their destructive rampage through the cartilage and bone. When the scientists developed and injected an imitation of the protein into an animal model of rheumatoid arthritis, the disease process was halted.

"The bouncer molecule stopped the immune cells from going crazy," said lead author Harris Perlman, associate professor of rheumatology at Northwestern's Feinberg School. "Imagine destructive customers in a bar, and the bouncer says, 'You are going to behave!' That's P21. This discovery opens up a new avenue for future therapies, which are greatly needed for rheumatoid arthritis."

Previous research by the Feinberg team showed people with rheumatoid arthritis were low in P21, but the protein's role was unknown. The new study, which will be published in the journal Arthritis & Rheumatism, reveals the protein's vital role in keeping the immune cells in check.

Currently, there is no effective, nontoxic way to stop the hyperactive immune cells, Perlman said.

To develop the new approach, Perlman and his team tested five different parts, called peptides, of P21. He slipped each peptide into a "ghostlike" molecule that he injected into mice with a rheumatoid arthritis-like disease. The molecule secretly infiltrated the immune cells. After the seven-day trial, one of the tested peptides had calmed the overactive immune cells without toxic effects. Next, Perlman plans a 30-day study with the same peptide to monitor efficacy and toxicity over a longer period of time.

Existing treatments for rheumatoid arthritis include low-level chemotherapy and steroids. These are not always effective, however, and they are frequently accompanied by side effects. A newer class of therapy, which is sometimes used in combination with chemotherapy and steroids, is biologic response modifiers. These are antibodies or other proteins that reduce the inflammation produced by the hyperactive immune cells. These biologics don't work for everyone, though, and can be associated with side effects including the risk of infection.

One of my favorites that she had was done by John Roeder. It's of a swamp house on a bayou and has a Louisiana feel to it.My sister also shares my love for folk art. It's called First Trolley to Van Nuys and shows the center of a town filled with people. It is done in enamel.There is a water scene that I really like painted in 1940. Maybe it's because I spent a lot of time with my grandmother and her house was full of them.I have loved folk art paintings since.....

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. The new study, which will be published in the journal Arthritis & Rheumatism, reveals the protein's vital role in keeping the immune cells in check. Provided by British Medical Journal (news : web) Public release date: 7-Sep-2011 [ | E-mail | Share ] Contact: Marla PaulMarla-Paul@northwestern. To develop the new approach, Perlman and his team tested five different parts, called peptides, of P21." Previous research by the Feinberg team showed people with rheumatoid arthritis were low in P21, but the protein's role was unknown. A newer class of therapy, which is sometimes used in combination with chemotherapy and steroids, is biologic response modifiers. Currently, there is no effective, nontoxic way to stop the hyperactive immune cells, Perlman said. In all, this provided information on more than 40,000 patients and almost 150,000 cumulative years of exposure to these drugs. But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors over the long term were at increased risk of cancer either. When the scientists developed and injected an imitation of the protein into an animal model of rheumatoid arthritis, the disease process was halted. These biologics don't work for everyone, though, and can be associated with side effects including the risk of infection.edu312-503-8928Northwestern University New 'bouncer' molecule halts rheumatoid arthritisProtective protein prevents immune system from ravaging joints and bones CHICAGO -- Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. Next, Perlman I'll find someone to give it to. I don't particularly care for his art. It's a beautiful painting but it's just too depressing to hang anywhere. Maybe it's because I spent a lot of time with my grandmother and her house was full of them. It's called First Trolley to Van Nuys and shows the center of a town filled with people.There is a water scene that I really like painted in 1940. Now we're very close. I saw a painting he did of a fishing scene but I chose not to buy it. It was painted in 1988 by Reverend Howard Finster and is done in enamel. When she died, she left me the painting and it hangs in a place of honor over my fireplace mantle. I don't know whose smile is bigger, the one in the painting or the one on my face every time I look at it. It is done in vibrant colors and also depicts the buildings in the market like an ice cream parlor and the Hotel Van Nuys.The painting that has touched me the most features a sad little girl and is called A Letter From My Mother. It's of a swamp house on a bayou and has a Louisiana feel to it. I have a friend who collects these and I found one of a woman reclining in a hammock. It's called Alligator Fisher and I'm thinking about getting because it reminds me of my cajun heritage, most of my family is from Louisiana.I have loved folk art paintings since I was a child. It's too bad my parents didn't let her play football with us. It's pretty funny to me that when we were growing up, she'd cry because she wasn't allowed to play football with the boys and

rthritis rheumatoid athritis rheumatoid arhritis rheumatoid artritis rheumatoid arthitis rheumatoid arthrtis rheumatoid arthriis rheumatoid arthrits rheumatoid arthriti rheumatoid arthritis heumatoid arthritis reumatoid arthritis rhumatoid arthritis rhematoid arthritis rheuatoid arthritis rheumtoid arthritis rheumaoid arthritis rheumatid arthritis rheumatod arthritis rheumatoi srthritis rheumatoid aethritis rheumatoid atthritis rheumatoid arrhritis rheumatoid aryhritis rheumatoid artgritis rheumatoid artjritis rheumatoid artheitis rheumatoid arthtitis rheumatoid arthrutis rheumatoid arthrotis rheumatoid arthriris rheumatoid arthriyis rheumatoid arthritus rheumatoid arthritos rheumatoid arthritia rheumatoid arthritid rheumatoid arthritis eheumatoid arthritis theumatoid arthritis rgeumatoid arthritis rjeumatoid arthritis rhwumatoid arthritis rhrumatoid arthritis rheymatoid arthritis rheimatoid arthritis rheunatoid arthritis rheumstoid arthritis rheumaroid arthritis rheumayoid arthritis rheumatiid arthritis rheumatpid arthritis rheumatoud arthritis rheumatood arthritis rheumatois arthritis rheumatoif rathritis rheumatoid atrhritis rheumatoid arhtritis rheumatoid artrhitis rheumatoid arthirtis rheumatoid arthrtiis rheumatoid arthriits rheumatoid arthritsi rheumatoid arthriti srheumatoid arthritis hreumatoid arthritis rehumatoid arthritis rhuematoid arthritis rhemuatoid arthritis rheuamtoid arthritis rheumtaoid arthritis rheumaotid arthritis rheumatiod arthritis rheumatodi arthritis rheumatoi aarthritis rheumatoid arrthritis rheumatoid artthritis rheumatoid arthhritis rheumatoid arthrritis rheumatoid arthriitis rheumatoid arthrittis rheumatoid arthritiis rheumatoid arthritiss rheumatoid arthritis rrheumatoid arthritis rhheumatoid arthritis rheeumatoid arthritis rheuumatoid arthritis rheummatoid arthritis rheumaatoid arthritis rheumattoid arthritis rheumatooid arthritis rheumatoiid arthritis rheumatoidd

Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.

Inflammatory arthritis has been linked to an increased risk of some cancers, such as lymphoma and lung cancer, but a lower risk of others, such as bowel and breast cancers. But it has been unclear to what extent tumour necrosis factor (TNF) inhibitors - drugs which act on the immune system - might affect risk.

TNF inhibitors include the monoclonal antibodies infliximab and adalimumab and the protein etanercept.

The researchers base their findings on 21 studies and eight conference abstracts, which met their strict inclusion criteria of reporting data on cancer associated with TNF inhibitors. In all, this provided information on more than 40,000 patients and almost 150,000 cumulative years of exposure to these drugs.

The studies were drawn from an extensive trawl of clinical research databases, and findings presented to the American College of Rheumatology, the European League against Rheumatism, and the British Society for Rheumatology between 1998 and 2010.

The pooled risk from seven studies for the development of any cancer showed that there was negligible or no increased risk, overall.

Two studies indicated that there was no evidence that patients taking TNF inhibitors over the long term were at increased risk of cancer either. And although patients who had had cancer before were more likely to be diagnosed with the disease again, this was not affected by the use of TNF inhibitors.

But four studies showed that patients treated with these drugs were 45% more likely to develop skin cancer other than melanoma, with two studies indicating that patients taking TNF inhibitors were 79% more likely to develop a melanoma than patients not taking these drugs.

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," write the authors. "However, it does appear to increase the risk of skin cancer, including melanoma," they add.

Provided by British Medical Journal (news : web)

Public release date: 7-Sep-2011
[ | E-mail | Share ]

Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University

New 'bouncer' molecule halts rheumatoid arthritis

Protective protein prevents immune system from ravaging joints and bones

CHICAGO -- Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons.

The Feinberg School team has identified this bouncer, a protein called P21, which prevents immune cells from launching into their destructive rampage through the cartilage and bone. When the scientists developed and injected an imitation of the protein into an animal model of rheumatoid arthritis, the disease process was halted.

"The bouncer molecule stopped the immune cells from going crazy," said lead author Harris Perlman, associate professor of rheumatology at Northwestern's Feinberg School. "Imagine destructive customers in a bar, and the bouncer says, 'You are going to behave!' That's P21. This discovery opens up a new avenue for future therapies, which are greatly needed for rheumatoid arthritis."

Previous research by the Feinberg team showed people with rheumatoid arthritis were low in P21, but the protein's role was unknown. The new study, which will be published in the journal Arthritis & Rheumatism, reveals the protein's vital role in keeping the immune cells in check.

Currently, there is no effective, nontoxic way to stop the hyperactive immune cells, Perlman said.

To develop the new approach, Perlman and his team tested five different parts, called peptides, of P21. He slipped each peptide into a "ghostlike" molecule that he injected into mice with a rheumatoid arthritis-like disease. The molecule secretly infiltrated the immune cells. After the seven-day trial, one of the tested peptides had calmed the overactive immune cells without toxic effects. Next, Perlman plans a 30-day study with the same peptide to monitor efficacy and toxicity over a longer period of time.

Existing treatments for rheumatoid arthritis include low-level chemotherapy and steroids. These are not always effective, however, and they are frequently accompanied by side effects. A newer class of therapy, which is sometimes used in combination with chemotherapy and steroids, is biologic response modifiers. These are antibodies or other proteins that reduce the inflammation produced by the hyperactive immune cells. These biologics don't work for everyone, though, and can be associated with side effects including the risk of infection.